Analysts interpret the drug's trial data as a key derisking ...
Analysts interpret the drug's trial data as a key derisking event for Vertex's stock, hinting at a potential blockbuster product. Concerns, however, are expressed over the absence of a placebo in the chronic neuropathic pain trial.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000031939166a6c62e.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment